HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
HC韋恩賴特公司重申對aurinia pharmaceuticals的買入評級,維持13美元的目標股價
HC Wainwright & Co. analyst Ed Arce reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and maintains $13 price target.
HC Wainwright分析師Ed Arce重申對Aurinia Pharmaceuticals (納斯達克:AUPH)的買入評級,並維持目標價格爲13美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。